Atorvastatin-induced severe thrombocytopenia

González-Ponte, Maria Luisa; González-Ruiz, Mario; Duvós, Elena; Gutiérrez-Iñiguez, M.Angeles; Olalla, Jose Ignacio; Conde, Eulogio

doi:10.1016/s0140-6736(05)70491-8

Cited by 30 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But is has also been shown that a positive temporal relation between the onset of symptoms and drug challenge may not always be seen 6. A clinical trial on drug-induced thrombocytopenia in 309 patients did not identify statins as the culprit,6 but there certainly have been case reports related to simvastatin and atorvastatin-induced thrombocytopenic purpura 7 , 8…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin-related thrombocytopenic purpura

Narayanan

2010

Case Reports

View full text Add to dashboard Cite

A 44-year-old male patient with a single vessel ischaemic heart disease was referred to the lipid clinic for management of hypercholesterolaemia after an episode of admission with thrombocytopenic purpura secondary to atorvastatin. Atorvastatin was discontinued and his platelet counts improved gradually with steroids. He is now established on a different statin with no further episodes of thrombocytopenia. Though a drug challenge was never done, an idiosyncratic reaction to the initial statin seems to be the most likely cause.

show abstract

Section: Discussionmentioning

confidence: 99%

Atorvastatin-related thrombocytopenic purpura

Narayanan

2010

Case Reports

View full text Add to dashboard Cite

show abstract

“…We performed a longitudinal cohort study of a diagnostic test, nested in a Phase II, single-center, double-blind TB treatment trial in Rio de Janeiro, Brazil [14]. The aims of the treatment trial were to evaluate and compare the antimicrobial activity of two daily TB treatment regimens administered during the first 8 weeks of treatment in patients with pulmonary TB.…”

Section: Methodsmentioning

confidence: 99%

T-SPOT.TBresponses during treatment of pulmonary tuberculosis

et al. 2009

View full text Add to dashboard Cite

BackgroundImmune responses to Mycobacterium tuberculosis antigens could serve as surrogate markers of treatment response.MethodsUsing the T-SPOT.TB assay and frozen peripheral blood mononuclear cells, we enumerated ESAT-6- and CFP-10-specific IFN-γ-producing T cells over time in pulmonary TB patients receiving directly observed treatment. T cell responses (measured as "spot forming cells" or "SFCs") were assessed prior to treatment and at 16 and 24 weeks of treatment.Results58 patients were evaluated, of whom 57 were HIV seronegative. Mean (SD) ESAT-6, CFP-10, and summed RD1 specific SFCs declined from 42.7 (72.7), 41.2 (66.4), and 83.8 (105.7) at baseline to 23.3 (39.4, p = 0.01), 23.2 (29.4, p = 0.18), and 46.5 (59.5, p = 0.02) at completion of 24 weeks of treatment, respectively. Only 10% of individuals with a baseline reactive test reverted to negative at treatment week 24. For the group that was culture positive at completion of 8 weeks of treatment compared to the culture negative group, the incidence rate ratio (IRR) of ESAT-6, CFP-10, and summed RD1 specific SFC counts were, respectively, 2.23 (p = 0.048), 1.51 (p = 0.20), and 1.83 (p = 0.047). Patients with cavitary disease had mean ESAT-6 specific SFC counts that were higher than those without cavitary disease (IRR 2.08, p = 0.034).ConclusionIFN-γ-producing RD1-specific T cells, as measured in the T-SPOT.TB assay, may be directly related to bacterial load in patients undergoing treatment for pulmonary TB. However, high inter-subject variability in quantitative results coupled with failure of reversion to negative of qualitative results in most subjects at treatment completion may limit the utility of this assay as a surrogate marker for treatment efficacy.

show abstract

“…Myopathy, rhabdomyolysis, and liver enzyme abnormalities are rare, but major side effects seen with statin use [5,6]. A few case reports of statin-induced thrombocytopenia, specifically with atorvastatin, rosuvastatin, and simvastatin [7][8][9][10][11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%

Atorvastatin-Induced Refractory Thrombocytopenia

Ghuman¹,

Manasewitsch²,

Ghuman³

et al. 2021

Cureus

View full text Add to dashboard Cite

Drug-induced thrombocytopenia is rarely associated with statin medications. We describe the case of a 69-year-old woman who developed refractory thrombocytopenia following atorvastatin use. To our knowledge, this is the fourth reported case of atorvastatin-induced thrombocytopenia and the first reported case of atorvastatin-induced refractory thrombocytopenia. Additionally, we summarize the cases of statin-induced thrombocytopenia reported in the medical literature.

show abstract

Atorvastatin-induced severe thrombocytopenia

Cited by 30 publications

References 3 publications

Atorvastatin-related thrombocytopenic purpura

Atorvastatin-related thrombocytopenic purpura

T-SPOT.TBresponses during treatment of pulmonary tuberculosis

Atorvastatin-Induced Refractory Thrombocytopenia

Contact Info

Product

Resources

About